Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis
Open Access
- 31 July 2017
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 35 (8) , 845-858
Abstract
Background Genomic tests may improve the stratification of patients to receive new therapies in several disease areas. However, the use of expensive targeted therapies can impact on the cost effectiveness of these tests. This study presents an economic evaluation of genomic testing in chronic lymphocytic leukaemia in the context of the UK National Health Service. Methods Cost-effectiveness and cost-utility analyses (using life-years and quality-adjusted life-years) were undertaken from a National Health Service and societal perspective. Five strategies were evaluated across several age groups using Markov modelling: three strategies that reflected varying current genetic testing practice and two configurations of genomic testing (including ibrutinib treatment). Results Genomic testing strategies yielded the most life-years/quality-adjusted life-years per patient, but were not cost effective compared with a threshold of £30,000 per life-year/quality-adjusted life-year gained. Cost-effectiveness acceptability curves indicated that there was some uncertainty surrounding this result. A genomic testing strategy becomes the most cost-effective option if a higher end-of-life cost-effectiveness threshold of £50,000 is applied, if a societal costing perspective is considered in 25-year-old patients or if the cost of ibrutinib treatment falls. Conclusion Stratifying patients with chronic lymphocytic leukaemia to targeted treatment using genomic testing improves health outcomes, but will likely only represent a cost-effective use of limited National Health Service resources if a higher cost-effectiveness threshold or societal costing perspective is applied, or if the price of ibrutinib treatment is reduced. This result may be broadly indicative of the likely cost effectiveness of other genomic tests that inform the stratification of patients to high cost-targeted therapies.Keywords
Funding Information
- National Institute for Health and Care Research (DRF-2011-04-021)
- Wellcome (090532/Z/09/Z, WT091989/Z/10/Z)
- Health Innovation Challenge Fund (HICF-1009-026)
This publication has 46 references indexed in Scilit:
- Cost of illness and economic burden of chronic lymphocytic leukemiaOrphanet Journal of Rare Diseases, 2013
- Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemiaBritish Journal of Haematology, 2012
- UPDATE OF THE DUTCH MANUAL FOR COSTING IN ECONOMIC EVALUATIONSInternational Journal of Technology Assessment in Health Care, 2012
- Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemiaLeukemia, 2012
- Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemiaBlood, 2011
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 2010
- Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility studyHealth and Quality of Life Outcomes, 2010
- Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trialBlood, 2009
- Whole-Genome Scanning by Array Comparative Genomic Hybridization as a Clinical Tool for Risk Assessment in Chronic Lymphocytic LeukemiaThe Journal of Molecular Diagnostics, 2008
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008